ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report)'s share price shot up 6.1% during mid-day trading on Friday . The company traded as high as $9.50 and last traded at $9.69. 2,631,441 shares changed hands during trading, a decline of 18% from the average session volume of 3,220,574 shares. The stock had previously closed at $9.13.
Analyst Ratings Changes
Separately, Canaccord Genuity Group reissued a "buy" rating and issued a $11.00 price target on shares of ASP Isotopes in a research note on Wednesday. Two equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $7.75.
Check Out Our Latest Analysis on ASPI
ASP Isotopes Stock Performance
The company has a current ratio of 14.72, a quick ratio of 14.56 and a debt-to-equity ratio of 3.53. The stock has a market capitalization of $899.34 million, a price-to-earnings ratio of -16.08 and a beta of 3.35. The firm's fifty day moving average price is $9.31 and its 200 day moving average price is $7.27.
ASP Isotopes (NASDAQ:ASPI - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.92). The firm had revenue of $1.20 million during the quarter, compared to analyst estimates of $1.60 million. ASP Isotopes had a negative net margin of 2,181.62% and a negative return on equity of 239.22%. Analysts forecast that ASP Isotopes Inc. will post -0.24 EPS for the current fiscal year.
Insider Activity at ASP Isotopes
In other news, CEO Paul Elliot Mann sold 81,077 shares of the company's stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $8.39, for a total value of $680,236.03. Following the completion of the transaction, the chief executive officer owned 8,084,191 shares in the company, valued at approximately $67,826,362.49. This represents a 0.99% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Robert Ainscow sold 8,438 shares of the firm's stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $8.53, for a total value of $71,976.14. Following the transaction, the chief operating officer directly owned 1,411,554 shares in the company, valued at approximately $12,040,555.62. This represents a 0.59% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 245,591 shares of company stock worth $2,139,790. Company insiders own 21.40% of the company's stock.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the company. Two Sigma Investments LP purchased a new stake in ASP Isotopes during the 4th quarter worth $1,980,000. BNP Paribas Financial Markets acquired a new stake in shares of ASP Isotopes in the 4th quarter worth about $34,000. ProShare Advisors LLC bought a new stake in ASP Isotopes during the 4th quarter valued at $67,000. Deutsche Bank AG raised its position in shares of ASP Isotopes by 25.2% during the 4th quarter. Deutsche Bank AG now owns 33,587 shares of the company's stock worth $152,000 after buying an additional 6,763 shares in the last quarter. Finally, Philadelphia Financial Management of San Francisco LLC raised its stake in shares of ASP Isotopes by 11.2% in the 1st quarter. Philadelphia Financial Management of San Francisco LLC now owns 3,508,062 shares of the company's stock worth $16,453,000 after buying an additional 354,517 shares in the last quarter. Institutional investors and hedge funds own 16.80% of the company's stock.
About ASP Isotopes
(
Get Free Report)
ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ASP Isotopes, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ASP Isotopes wasn't on the list.
While ASP Isotopes currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
